Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Sapu Nano Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway

SAN DIEGO, US - Media OutReach Newswire - 9 July 2026 - Sapu Nano (US) LLC, a clinical-stage biotechnology company developing the proprietary Deciparticle™ nanomedicine platform, today announced that the independent Safety Review Committee (SRC) has completed its review of the initial safety cohort in the Company's ongoing SP-03-B101 Phase 1b clinical trial evaluating Sapu003, an investigational intravenous formulation of everolimus.



Following completion of the protocol-defined 28-day dose-limiting toxicity (DLT) evaluation period for the initial three-patient cohort, the SRC concluded that no dose-limiting toxicities were observed and recommended advancing the study to the next planned dose level. Enrollment into the second dose cohort has commenced.

SP-03-B101 is an open-label, multicenter, Bayesian Optimal Interval (BOIN) dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of weekly intravenous Sapu003 in patients with advanced mTOR-sensitive solid tumors. The study is registered on ClinicalTrials.gov (Identifier: NCT07369505).

Following successful completion of the initial safety cohort, the Company has initiated expansion of the SP-03-B101 clinical program into Europe, broadening patient access and supporting the global clinical development strategy for Sapu003.

"The independent Safety Review Committee's recommendation to advance to the next dose level provides important clinical validation of the Sapu003 program," said Dr. Vuong Trieu, Chief Executive Officer of Sapu Nano. "Combined with the expansion of SP-03-B101 into Europe, these milestones position Sapu003 for accelerated clinical development while broadening access for patients with advanced mTOR-sensitive solid tumors."

Peer-Reviewed Publication Supports Clinical Development

The clinical milestone follows the Company's recent peer-reviewed publication describing the scientific foundation of Sapu003 and the Deciparticle™ platform:

Min SH, Forero K, Putnam W, Anderson J, Hoff R, Lopp J, Trieu V, Ho K, Lee C. Intravenous Everolimus Formulation (Sapu003) for Clinical Trials. International Journal of Molecular Sciences. 2026;27(13):5775. doi: 10.3390/ijms27135775.

The publication provides the first comprehensive description of the Deciparticle™ platform and describes a stable intravenous everolimus nanoparticle formulation with a mean particle size below 20 nanometers, identification of mPEG-Chol as the optimal carrier, a scalable cGMP manufacturing process suitable for clinical production, and potent preclinical antitumor activity.

Clinical Trial Information

Study Title: SP-03-B101: A Phase 1b Study of Sapu003 (Intravenous Everolimus) in Patients with Advanced mTOR-Sensitive Solid Tumors

ClinicalTrials.gov Identifier: NCT07369505

About Sapu003

Sapu003 is an investigational intravenous formulation of everolimus developed using Sapu Nano's proprietary Deciparticle™ nanoparticle platform. Sapu003 is designed to overcome the formulation limitations associated with oral everolimus by enabling intravenous administration with a scalable cGMP manufacturing process. The program is currently being evaluated in the Phase 1b SP-03-B101 clinical trial in patients with advanced mTOR-sensitive solid tumors.

About Sapu Nano's Deciparticle™

Sapu Nano's Deciparticle™ is a proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.



Hashtag: #SapuNano

The issuer is solely responsible for the content of this announcement.

About Sapu Nano

Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. For more information, visit www.sapunano.com.

News from Asia

The Hoffman Agency Taps Darren Burns as Asia Pacific President

Appointment builds on the independent consultancy's global ambitionsSILICON VALLEY, USA – Media OutReach Newswire – 17 November 2026 – The Hoffman Agency, an independent global communications cons...

KFC Thailand Breaks Creative Boundaries in 2026 with Bold Campaigns and Its First-Ever Original Manga "Dumb Luck"

Turning Cultural Insights, Pop Culture and Everyday Moments into Unexpected and Unforgettable Brand ExperiencesBANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 – KFC Thailand has bee...

From Black Friday to Christmas: Garvee Unveils a Holiday Gift Guide for the Year-End Shopping Season

ONTARIO, CANADA – Media OutReach Newswire – 17 November 2026 – With Black Friday, Cyber Monday and Christmas just around the corner, it's time to start thinking about gifts for family, friends and...

CHAGEE Grows to Eight Asia Pacific Markets with Brunei Entry; Unveils New Rooted in Tea Store Design

In the new design, tea is not just what CHAGEE serves, but what shapes the spaceSINGAPORE – Media OutReach Newswire – 17 November 2026 – CHAGEE is growing its family in Asia Pacific, opening its f...

Century-Old Guizhou Time-Honored Brand "Laishigang Sauce-Aroma Baijiu" Establishes Foothold in Hong Kong to Launch Southeast Asian and International Expansion Strategy

HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – Guizhou Laishigang Liquor Co., Ltd. ("Laishigang Liquor"), a fifth-generation, century-old sauce-aroma baijiu producer certified as a ...

THE WORLD ENDS 2026 Connects Asia’s Creative and Design Networks to Unlock New Business Opportunities

International design platform brings together creative talent, industry partners and regional business networks, targeting 200 buyer–seller connections to foster business collaboration and cross-bo...

Ayara Kamala Reveals a Refreshed Vision for Wellness in Phuket

BANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 - Ayara Kamala Resort & Spa, an intimate haven nestled along Phuket's prestigious Kamala coastline, has officially unveiled its r...

China-Indonesia Cultural Industry Exchange Symposium Held in Jakarta

JAKARTA, INDONESIA – Media OutReach Newswire – 17 November 2026 – On the afternoon of November 13, the China-Indonesia Cultural Industry Exchange Symposium, co-hosted by the China Intercontinental...

Disney and Visa Announce Multi-Year Strategic Alliance Across Asia Pacific

The alliance spans Disney-branded card programmes, cardholder benefits and joint marketing initiatives across the regionHONG KONG SAR – Media OutReach Newswire – 17 November 2026 – The Walt Disney...

Galaxy Resort Presents: "Plácido Domingo & José Carreras: The Legends United Opera Gala"

Greater China and Macau's Only Performance Galaxy Rewards select members can enjoy privileged priority booking from 10 December 2026.Tickets go on public sale from 14 December 2026 CaptionMACAU SAR...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...